Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181636 · ClinicalTrials.gov registry record · NA
Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00181636: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00181636 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181636, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether the investigational drug galantamine-CR (Reminyl- Controlled Release capsule) is useful in improving problems with memory in bipolar patients with stable mood. This study is being done because a large proportion of patients with bipolar disorder experience significant memory problems, even when their mood is stable, after adequate treatment. These memory problems have been associated with poor daily social functioning. Studying galantamine-CR in this population may provide a new clinical way to combat memory problems in stable patients with bipolar disorder.
Interventions
- DRUG Galantamine-CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Est. Completion | 2006-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181636
The ClinicalTrials.gov registry entry for NCT00181636 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galantamine-CR is the first listed.
NCT00181636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181636 about?
NCT00181636 is a clinical study titled "Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder". The purpose of the study is to determine whether the investigational drug galantamine-CR (Reminyl- Controlled Release capsule) is useful in improving problems with memory in bipolar patients with stable mood. This study is being done because a large proportion of patients with bipolar disorder exper...
What is the current status of trial NCT00181636?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00181636?
The interventions under investigation include: Galantamine-CR (DRUG).
Who is sponsoring clinical trial NCT00181636?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.